论文部分内容阅读
本文报告慢性活动性类风湿性关节炎患者口服硫酸锌或安慰剂的双盲对照试验结果。 24例虽用常规治疗但仍有活动的慢性难治性类风湿性关节炎患者(平均病程11.3±6.7年)随机被指定口服硫酸锌(220毫克,每日3次)或安慰剂共12周(双盲期),继之所有患者均口服硫酸锌12周(公开期)。试验期间,患者原先的药物治疗仍保持不变。两组平均年龄、病程或关节受累数无明显差异。试验前和试验开始后2、4、8、12、16、20、24周时对
This article reports the results of a double-blind, controlled trial of oral zinc sulfate or placebo in patients with chronic active rheumatoid arthritis. Twenty-four patients with chronic refractory rheumatoid arthritis who were treated routinely (mean duration 11.3 ± 6.7 years) were randomized to receive either zinc sulfate (220 mg three times daily) or placebo for 12 weeks (Double-blind), followed by oral zinc sulphate in all patients for 12 weeks (open date). During the trial, the patient’s original medical treatment remained unchanged. There was no significant difference in average age, disease duration or joint involvement between the two groups. Right before test and after start of test 2,4,8,12,16,20,24 weeks